Last reviewed · How we verify
Bifidobacterium Bifidum Oral Capsule
Bifidobacterium bifidum is a live probiotic bacterium that colonizes the gut microbiota and promotes beneficial microbial balance.
Bifidobacterium bifidum is a live probiotic bacterium that colonizes the gut microbiota and promotes beneficial microbial balance. Used for Intestinal dysbiosis, Diarrhea-associated conditions, Digestive health support.
At a glance
| Generic name | Bifidobacterium Bifidum Oral Capsule |
|---|---|
| Also known as | Probiotics |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| Drug class | Probiotic |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
This probiotic strain works by establishing itself in the intestinal tract, where it produces short-chain fatty acids and other metabolites that support intestinal barrier function and modulate the immune system. By competing with pathogenic bacteria for nutrients and adhesion sites, it helps restore a healthy microbiota composition and may reduce intestinal inflammation and improve digestive health.
Approved indications
- Intestinal dysbiosis
- Diarrhea-associated conditions
- Digestive health support
Common side effects
- Gastrointestinal bloating
- Mild abdominal discomfort
- Transient diarrhea
Key clinical trials
- Probiotic Impact on Cognitive Performance, and Metabolic Outcomes in Overweight Young Adults With Impaired Glucose Regulation (NA)
- The Bloom Infant Probiotic (BIP) Study (PHASE2)
- Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children with Leukemia (PHASE2)
- Oral Probiotics for the Treatment and Prevention of Vulvovaginal Infections in Pregnancy - Double-blind, Randomized, Placebo-controlled Study (NA)
- Probiotics Combined with Enteral Nutrition Reduces Postoperative Infectious Complications in PD (PHASE1, PHASE2)
- Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan (PHASE2, PHASE3)
- Colonoscopic Probiotics Spray in Irritable Bowel Syndrome (NA)
- Effects of the Use of Probiotics on the Intestinal Microbiota of Patients With Gastric Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: